Misonix announced that it has entered into an agreement with Aesculap, to acquire back the rights to the remaining accounts, as of March 1, 2015, exclusively being managed by Aesculap for the Misonix BoneScalpel Ultrasonic Bone Cutting System.
Since December 2012, under a non-exclusive distribution agreement, Aesculap retained the right to sell BoneScalpel disposables in the United States to certain, limited hospital accounts which are covered by binding supply agreements for varying periods of time, but not to exceed 3 years.
The BoneScalpel is a novel ultrasonic surgical system used for safe, tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures.
"We are thankful to Aesculap and their professional management of, and efforts in, servicing these strategically important accounts," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.
Mr. McManus goes on to say, "This new agreement moves Misonix an important additional step further along the path of complete control of BoneScalpel distribution in the United States through the company’s own growing network of sales representatives."
Misonix designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies.
Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.